Saturday, November 23, 2024
Home 2023

Yearly Archives: 2023

Psychedelic News

Psycheceutical’s (BWVI) NeuroDirect™ Ketamine can Help Alleviate Headaches and Migraines Within...

Editor / Curator -
2023 Watch List

Psycheceutical Bioscience (BWVI) Secures Funding for Clinical Trials

Editor / Curator -
2023 Watch List

Hepion Pharma (HEPA). Artificial Intelligence (AI) to Speed Drug Development.

Editor / Curator -
Client

Acquisition of Certain Minerva-Rockdale Oil and Gas Leases and Field Equipment...

Editor / Curator -
Client

Principal Solar Comments on SEC Action

Editor / Curator -
Pressure Bioscience, Biotech Stock Review, Roland Rick Perry
2023 Watch List

Pressure Bioscience (PBIO) Meets Ohio State University. Pressure Testing on Food...

Editor / Curator -
2023 Watch List

Adding Pressure BioSciences (PBIO) $0.80 to Watch List.

Editor / Curator -
2023 Watch List

CEO Interview: Ric Schumacher Pressure Bioscience (PBIO).

Editor / Curator -
pRESSURE bIOSCIENCE
2023 Watch List

Pressure BioSciences (PBIO) Receives $1.5M Contract for UltraShear Nanoemulsified CBD.

Editor / Curator -
2022 Watch List

Asia-Pacific: A Region of Stability Amidst Economic Uncertainty

Editor / Curator -
1...101112...18Page 11 of 18

Latest article

Nine Page Summary Report on GeoVax (GOVX)

2024 Watch List Editor / Curator -
This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier...

GeoVax (GOVX) Provides First Half 2024 Business Update.

2024 Watch List Editor / Curator -
Award of BARDA Project NextGen contract represents a significant milestone event; Total value...

Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.

All News Editor / Curator -
Can You Imagine Selling Solgenix at $2.00 yesterday. And to be honest, news wasn't all that big - such...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: [email protected]
© Managed by Revelers.IO Media Group Inc.